2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.37: Early Experience With the FLAURA2 Regimen in Patients With NSCLC and EGFR Mutations in Latin America

PP01.37: Early Experience With the FLAURA2 Regimen in Patients With NSCLC and EGFR Mutations in Latin America

Pdf Summary

The document discusses early experiences with the FLAURA2 regimen for treating non-small cell lung cancer (NSCLC) with EGFR mutations in a cohort of patients from Latin America. The study focuses on patients with advanced EGFR-mutated NSCLC treated using the FLAURA2 regimen, which combines osimertinib and chemotherapy. The regimen targets patients with exon 19 deletions or L858R mutations, showing an improvement in progression-free survival (PFS) compared to osimertinib monotherapy.<br /><br />Key findings include the mean age of patients being 62 years, with the majority being male and non-smokers. Most had baseline cerebral involvement, and two significant mutations were reported in the cohort: 52.6% had exon 19 deletions and 47.4% the L858R mutation.<br /><br />The study found an overall response rate of 84.3%, with some patients achieving a complete response early on. The PFS was 7.9 months, and the overall survival data, though immature, was at 11.3 months. The main reasons for choosing this regimen were central nervous system involvement, disease burden, symptoms, and the presence of the L858R mutation.<br /><br />Toxicity was noted, with grade 3 adverse events affecting 52.6% of patients, and one patient died due to febrile neutropenia. Approximately 63.2% reported adequate tolerance to the treatment, although 18.4% found the toxicity to be more significant than expected. The study concludes that while the FLAURA2 regimen demonstrates efficacy, the increased toxicity warrants further investigation with a larger patient cohort and a longer follow-up to assess the long-term impact and safety of treatment.

Asset Subtitle

Liliana Gutierrez

Keywords

FLAURA2 regimen

non-small cell lung cancer

EGFR mutations

osimertinib

chemotherapy

exon 19 deletions

L858R mutation

progression-free survival

Latin America

toxicity